(1R,2S,3R,4R)-1-(methylamino)pentane-1,2,3,4,5-pentol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1R,2S,3R,4R)-1-(methylamino)pentane-1,2,3,4,5-pentol
• 化学式: C₆H₁₅NO₅
• 分子量: 181.19
• InChiKey: JPLFILAQMVZKLE-ARQDHWQXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  113
• 氢给体数：
  6
• 氢受体数：
  6

文献信息

• PROCESS FOR THE PREPARATION OF CHELATED COMPOUND
  申请人：Maisano Federico

  公开号：US20120245333A1

  公开（公告）日：2012-09-27

  The present invention generally relies on a process for the preparation of chelated compounds, comprising the selective interaction between a solid matrix and a chelating agent. In more details, the present invention enables the preparation of chelated compounds useful as diagnostic agents, in high yields and in a reliable way.

  本发明通常依赖于一种制备螯合化合物的过程，包括固体基质和螯合剂之间的选择性相互作用。更具体地说，本发明使得高产率和可靠的制备螯合化合物作为诊断剂成为可能。
• Modafinil compositions
  申请人：Hickey Bourghol Magali

  公开号：US20070021510A1

  公开（公告）日：2007-01-25

  Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.

  利用共晶和溶剂化物形成了混合型、对映纯和对映混合型莫达非尼晶体，并调控了几个重要的物理特性。可以调控莫达非尼的溶解度、溶解度、生物利用度、剂量反应和稳定性，以提高制药组合物的疗效。
• Pharmaceutical co-crystal compositions
  申请人：Almarsson Orn

  公开号：US20070026078A1

  公开（公告）日：2007-02-01

  A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

  一种药物组合物，包括API和共晶形成剂的共晶体；其中，API具有至少一种从醚，硫醚，醇，硫醇，醛，酮，硫酮，硝酸酯，磷酸酯，硫代磷酸酯，酯，硫酯，硫酸酯，羧酸，膦酸，亚磷酸，磺酸，酰胺，一级胺，二级胺，氨，三级胺，sp2胺，硫氰酸盐，氰胺，肟，腈，重氮，有机卤化物，硝基，s-杂环环，噻吩，n-杂环环，吡咯，o-杂环环，呋喃，环氧化物，过氧化物，羟肟酸，咪唑，吡啶中至少一种官能团，而共晶形成剂具有至少一种从胺，酰胺，吡啶，咪唑，吲哚，吡咯烷，羰基，羧基，羟基，酚，磺酰，磺酰基，巯基和甲硫基中选择的官能团，使得API和共晶形成剂能够在结晶条件下从溶液相共结晶。
• Pharmaceutical Co-Crystal Compositions and Related Methods of Use
  申请人：McMahon Jennifer

  公开号：US20070299033A1

  公开（公告）日：2007-12-27

  The present invention comprises pharmaceutical compositions comprising a co-crystal of an API and a co-crystal former, and methods of making and using the same.

  本发明涉及制备药物组合物，其中包括API和共晶形成剂的共晶体，以及制备和使用该药物组合物的方法。
• US7566805B2
  申请人：——

  公开号：US7566805B2

  公开（公告）日：2009-07-28